Brokerages Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Price Target at $13.86

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have been given a consensus rating of “Hold” by the nine brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $13.8571.

Several equities research analysts recently issued reports on the company. Citigroup reiterated a “market outperform” rating on shares of Bicycle Therapeutics in a report on Wednesday, June 3rd. Wall Street Zen raised Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Needham & Company LLC cut their price target on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Wednesday, July 8th.

Insider Buying and Selling at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 5,905 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total transaction of $25,214.35. Following the sale, the chief executive officer directly owned 605,408 shares of the company’s stock, valued at $2,585,092.16. This represents a 0.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 9,977 shares of company stock valued at $42,702 in the last ninety days. Insiders own 22.00% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Clearstead Advisors LLC grew its stake in shares of Bicycle Therapeutics by 234.2% in the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock worth $33,000 after acquiring an additional 3,262 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Bicycle Therapeutics by 512.9% in the second quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock valued at $33,000 after purchasing an additional 6,447 shares during the period. Pinnacle Wealth Management Advisory Group LLC purchased a new position in Bicycle Therapeutics in the fourth quarter valued at $71,000. Ausdal Financial Partners Inc. acquired a new position in Bicycle Therapeutics during the 2nd quarter worth $70,000. Finally, Vontobel Holding Ltd. acquired a new position in Bicycle Therapeutics during the 4th quarter worth $71,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Stock Down 2.8%

Shares of NASDAQ BCYC opened at $4.18 on Wednesday. The firm has a market cap of $292.56 million, a price-to-earnings ratio of -1.53 and a beta of 1.54. Bicycle Therapeutics has a 52-week low of $3.74 and a 52-week high of $9.16. The business’s 50 day moving average is $4.16 and its two-hundred day moving average is $4.53.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.14). Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%.The firm had revenue of $0.63 million for the quarter, compared to analysts’ expectations of $4.22 million. Analysts anticipate that Bicycle Therapeutics will post -2.26 EPS for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.